Disintegrating Oral Tablet Suitable For Active Pharmaceutical Ingredients
20210106534 · 2021-04-15
Assignee
Inventors
Cpc classification
A61K9/2018
HUMAN NECESSITIES
A61Q11/00
HUMAN NECESSITIES
A61K9/0056
HUMAN NECESSITIES
A61K9/2086
HUMAN NECESSITIES
International classification
Abstract
The invention relates to a disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and
the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.
Claims
1. A disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.
2. The oral tablet according to claim 1, wherein the non-DC sugar alcohol particles have not been granulated prior to tableting.
3. The oral tablet according to claim 1 or 2, wherein the non-DC sugar alcohol particles are essentially consisting of sugar alcohol.
4. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol particles are consisting of sugar alcohol.
5. The oral tablet according to any of the preceding claims, wherein the tablet comprises flavor in an amount of 1-10% by weight of the tablet.
6. The oral tablet according to any of the preceding claims, wherein the tablet is designed to release at least 50% by weight of the flavor within 20 seconds from onset of mastication.
7. The oral tablet according to any of the preceding claims, wherein the burst of the at least one flavor ingredient involves a burst of flavors to the lungs upon mastication.
8. The oral tablet according to any of the preceding claims, wherein the burst of the at least one flavor ingredient involves a burst of flavors to the nasal cavity upon mastication.
9. The oral tablet according to any of the preceding claims, wherein the at least one flavor ingredient comprises a volatile flavor.
10. The oral tablet according to any of the preceding claims, wherein the tablet is designed to disintegrate within 20 seconds from onset of mastication.
11. The oral tablet according to any of the preceding claims, wherein the tablet obtains the burst through salivation promoted by the non-DC sugar alcohol particles during mastication in combination with a resulting dissolving of sweetener.
12. The oral tablet according to any of the preceding claims, wherein the oral tablet is designed to disintegrate within 20 seconds of in vivo chewing, where the in vivo chewing is carried out by a chewing panel comprising at least 10 individuals, chewing at a rate of 60 chews per minute.
13. The oral tablet according to any of the preceding claims, wherein said population of particles is tableted into a first module and combined with a second population of particles that is tableted into a second module.
14. The oral tablet according to any of the preceding claims, wherein said population of particles is tableted into a first module and combined with a second population of particles that is tableted into a second module, and wherein the second module does not comprise non-DC sugar alcohol particles.
15. The oral tablet according to any of the preceding claims, wherein said population of particles is tableted into a first module and combined with a second population of particles that is tableted into a second module, and wherein the second module is different in composition than the first module.
16. The oral tablet according to any of the preceding claims, wherein said population of particles is tableted into a first module and combined with a second population of particles that is tableted into a second module, and wherein the second module is a an orally disintegrating tablet (ODT).
17. The oral tablet according to any of the preceding claims, wherein the non-DC areas are evenly distributed in the tablet or at least one module of the tablet.
18. The oral tablet according to any of the preceding claims, wherein a series of at least 10 of said tablets comprises said non-DC particles in an amount varying with a relative standard deviation (RSD) below 10%.
19. The oral tablet according to any of the preceding claims, wherein the non-DC areas are homogenously distributed in the tablet or at least one module of the tablet.
20. The oral tablet according to any of the preceding claims, wherein the tablet is a chewable tablet.
21. The oral tablet according to any of the preceding claims, wherein at least 20% by weight of the non-DC sugar alcohol particles have a particle size above 500 μm.
22. The oral tablet according to any of the preceding claims, wherein at least 30% by weight of the non-DC sugar alcohol particles have a particle size above 500 μm.
23. The oral tablet according to any of the preceding claims, wherein at least 40% by weight of the non-DC sugar alcohol particles have a particle size above 500 μm.
24. The oral tablet according to any of the preceding claims, wherein at least 10% by weight of said population of particles have a particle size below 250 μm, and wherein at least 30% by weight of said population of particles have a particle size above 500 μm.
25. The oral tablet according to any of the preceding claims, wherein at least 10% by weight of the non-DC sugar alcohol particles have a particle size below 250 μm.
26. The oral tablet according to any of the preceding claims, wherein at least 5% by weight of the non-DC sugar alcohol particles have a particle size below 250 μm.
27. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol particles are selected from non-DC particles of erythritol, maltitol, xylitol, isomalt, lactitol, mannitol, and combinations thereof.
28. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol particles are selected from non-DC particles of erythritol, maltitol, xylitol, isomalt, and combinations thereof.
29. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol particles are selected from non-DC particles of erythritol, maltitol, xylitol, and combinations thereof.
30. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol particles are non-DC erythritol particles.
31. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol particles are non-DC xylitol particles.
32. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol particles are non-DC isomalt particles.
33. The oral tablet according to any of the preceding claims, wherein the tablet comprises said non-DC sugar alcohol particles in an amount of at least 10% by weight of the tablet.
34. The oral tablet according to any of the preceding claims, wherein the tablet comprises said non-DC sugar alcohol particles in an amount of at least 20% by weight of the tablet.
35. The oral tablet according to any of the preceding claims, wherein the tablet comprises said non-DC sugar alcohol particles in an amount of at least 30% by weight of the tablet.
36. The oral tablet according to any of the preceding claims, wherein the first module comprises said non-DC sugar alcohol particles in an amount of at least 30% by weight of the first module.
37. The oral tablet according to any of the preceding claims, wherein the first module comprises said non-DC sugar alcohol particles in an amount of at least 40% by weight of the first module.
38. The oral tablet according to any of the preceding claims, wherein said DC sugar alcohol particles comprises sugar alcohols selected from DC particles of sorbitol, erythritol, xylitol, lactitol, maltitol, mannitol, isomalt, and combinations thereof.
39. The oral tablet according to any of the preceding claims, wherein the tablet comprises said DC sugar alcohol particles in an amount of at least 10% by weight of the tablet.
40. The oral tablet according to any of the preceding claims, wherein the tablet comprises said DC sugar alcohol particles in an amount of at least 20% by weight of the tablet.
41. The oral tablet according to any of the preceding claims, wherein the tablet comprises said DC sugar alcohol particles in an amount of at least 30% by weight of the tablet.
42. The oral tablet according to any of the preceding claims, wherein the first module comprises said DC sugar alcohol particles in an amount of at least 30% by weight of the first module.
43. The oral tablet according to any of the preceding claims, wherein the second module comprises DC sugar alcohol particles in an amount of at least 50% by weight of the second module.
44. The oral tablet according to any of the preceding claims, wherein the second module comprises DC sugar alcohol particles in an amount of at least 70% by weight of the second module.
45. The oral tablet according to any of the preceding claims, wherein the second module comprises DC sugar alcohol particles in an amount of at least 90% by weight of the second module.
46. The oral tablet according to any of the preceding claims, wherein friability of the tablet is less than 3%, such as less than 2%, such as less than 1.5%, wherein friability is measured according to European Pharmacopoeia 9.1, test method 2.9.7. by using a pharmaceutical friability-tester PTF 10E from Pharma Test.
47. The oral tablet according to any of the preceding claims, wherein the tablet comprises one or more binders other than binders forming part of the DC sugar alcohol particles in an amount of 0.1 to 6% by weight of the tablet.
48. The oral tablet according to any of the preceding claims, wherein the resistance to crunching of the tablet is greater than 60N, such as greater than 70N, such as greater than 80N, such as greater than 90N, such as greater than 100 N, such as greater than 110, such as greater than 130N such as greater than 150N, wherein the resistance to crunching of the tablet is less than 300N, such as less than 250N, such as less than 200N, wherein the resistance to crunching is determined according to European Pharmacopoeia 9.1, test method 2.9.8. by using a pharmaceutical resistance to crunching tester model Pharma Test type PTB 311.
49. The oral tablet according to any of the preceding claims, wherein the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.2 and 1.2.
50. The oral tablet according to any of the preceding claims, wherein the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.3 and 1.0.
51. The oral tablet according to any of the preceding claims, wherein the tablet has a weight ratio between said non-DC sugar alcohol particles and said DC sugar alcohol particles, which is between 0.3 and 0.7.
52. The oral tablet according to any of the preceding claims, wherein the non-DC areas results in induced saliva generation.
53. The oral tablet according to any of the preceding claims, wherein saliva generation upon mastication of the tablet is induced compared to a tablet without non-DC sugar alcohol particles.
54. The oral tablet according to any of the preceding claims, wherein saliva generation upon mastication of the tablet is induced compared to a tablet where the discrete areas are based on DC sugar alcohol particles.
55. The oral tablet according to any of the preceding claims, wherein the tablet generates more than 1.5 mL saliva within 30 seconds from onset of mastication.
56. The oral tablet according to any of the preceding claims, wherein the tablet generates more than 1.5 mL saliva within a period from 30 to 90 seconds from onset of mastication.
57. The oral tablet according to any of the preceding claims, wherein the tablet generates more than 1.5 mL saliva within a period from 90 to 180 seconds from onset of mastication.
58. The oral tablet according to any of the preceding claims, wherein the tablet generates more than 1.5 mL saliva within a period from 180 to 300 seconds from onset of mastication.
59. The oral tablet according to any of the preceding claims, further comprising at least one viscosity modifier.
60. The oral tablet according to any of the preceding claims, wherein the at least one viscosity modifier is selected from the group consisting of sodium alginate, pectin, carrageenan, xanthan gum, acacia gum and mixtures thereof.
61. The oral tablet according to any of the preceding claims, further comprising at least one viscolising agent that when hydrated forms a gel having positive surface electrical charge and at least one viscolising agent that when hydrated forms a gel having negative surface electrical charge.
62. The oral tablet according to any of the preceding claims, wherein the tablet comprises an active ingredient.
63. The oral tablet according to any of the preceding claims, wherein the tablet comprises a self-emulsifying system that when hydrated with saliva upon oral administration forms an emulsion.
64. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers and one or more oil carriers.
65. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers, one or more oil carriers and one or more solubilizers.
66. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers, one or more oil carriers, one or more solubilizers and one or more solvents.
67. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers and one or more solvents.
68. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers that have both emulsifying and solubilizing properties.
69. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier and a carrier.
70. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers that act as both an emulsifier, a carrier and a solubilizer.
71. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more fatty acids, one or more glycerols, one or more waxes, one or more flavonoids and one or more terpenes.
72. The oral tablet according to any of the preceding claims, wherein the self-emulsifying system comprises one or more emulsifiers that have an HLB-value of more than 6, preferably of 8-18.
73. The oral tablet according to any of the preceding claims, wherein the one or more emulsifiers are selected from the group consisting of PEG-35 castor oil, PEG-6 oleoyl glycerides, PEG-6 linoleoyl glycerides, PEG-8 caprylic/capric glyceride, sorbitan monolaurate, sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (60) sorbitan monostearate, polyoxyethylene (80) sorbitan monooleate, lauroylpoloxyl-32 glycerides, stearoyl polyoxyl-32 glycerides, polyoxyl-32 stearate, propylene glycol mono laurate, propylene glycol di laurate, and mixtures and combinations thereof.
74. The oral tablet according to any of the preceding claims, wherein the one or more emulsifiers comprise PEG-35 castor oil.
75. The oral tablet according to any of the preceding claims, wherein the oil carrier is selected from the group consisting of natural fatty acids; medium-chain triglycerides of caprylic (C8) and capric (C10) acids; propylene glycol esters of caprylic (C8) and capric (C10) acids; mono-, di- and triglycerides of mainly linoleic (C18:2) and oleic (C18:1) acids; fatty acid 18:1 cis-9; natural fatty acids; mono-, di- and triglycerides of oleic (C18:1) acid, and mixtures and combinations thereof.
76. The oral tablet according to any of the preceding claims, wherein the one or more solvents are selected from the group consisting of polyglyceryl-3 dioleate, 1,2-propandiol, polyethylene glycol 300, polyethylene glycol 400, diethylene glycol monoethyl ether, and mixtures and combinations thereof.
77. The oral tablet according to any of the preceding claims, wherein the one or more solubilizers are selected from the group consisting of lauroylpoloxyl-32 glycerides; stearoyl polyoxyl-32 glycerides; Polyoxyl-32 stearate; synthetic copolymer of ethylene oxide (80) and propylene oxide (27); polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft co-polymer; alpha-, beta- or gamma cyclodextrins and derivatives thereof pea proteins (globulins, albumins, glutelins proteins); and mixtures and combinations thereof.
78. The oral tablet according to any of the preceding claims, wherein the tablet comprises an active pharmaceutical ingredient.
79. The oral tablet according to any of the preceding claims, wherein the tablet comprises an active pharmaceutical ingredient and a self-emulsifying system that when hydrated with saliva upon oral administration forms an emulsion.
80. The oral tablet according to any of the preceding claims, wherein the tablet comprises nicotine and a self-emulsifying system that when hydrated with saliva upon oral administration forms an emulsion.
81. The oral tablet according to any of the preceding claims, wherein the tablet comprises a lipophilic association between an active ingredient and a fatty acid, such as oleic acid.
82. The oral tablet according to any of the preceding claims, wherein the tablet comprises particles comprising gum base, and wherein the tablet is designed to be masticated into a coherent residual containing water-insoluble components.
83. The oral tablet according to any of the preceding claims, wherein the oral tablet contains particles comprising gum base, and wherein the gum base comprises at least 5% by weight of elastomer.
84. The oral tablet according to any of the preceding claims, wherein the tablet is free of gum base.
85. The oral tablet according to any of the preceding claims, wherein the oral tablet is essentially consisting of ingredients that are present in nature.
86. The oral tablet according to any of the preceding claims, wherein the oral tablet comprises a natural high intensity sweetener, such as stevioside.
87. The oral tablet according to any of the preceding claims, wherein the non-DC sugar alcohol is a non-DC sugar, such as a non-DC cane sugar.
88. A disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the tablet being designed to turn into liquid within 20 seconds of mastication.
89. A disintegrating oral tablet suitable for active pharmaceutical ingredients comprising a population of particles, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the tablet being designed to dissolve within 20 seconds of mastication.
90. The disintegrating oral tablet according to any of claim 88 or 89, wherein the tablet is composed according to any of claims 1-87.
91. A method of providing a burst of flavor, the method comprising the steps of: i) providing a disintegrating oral tablet comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, and ii) disintegrating the tablet by mastication and thereby generating a burst of flavor by means of a plurality of discrete non-DC areas in the tablet.
92. The method according to claim 91, wherein the tablet is composed according to any of claims 1-90.
93. A disintegrating oral product for providing a burst of flavor comprising a population of particles and at least one flavor ingredient, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles.
94. The disintegrating oral product according to claim 93, wherein the product is a powder.
95. The disintegrating oral product according to claim 93, wherein the product is a pouch.
96. The disintegrating oral product according to claims 93-95, wherein the product is composed according to any of claims 1-88.
Description
THE FIGURES
[0227] The invention will now be described with reference to the drawings where
[0228]
[0229]
[0230]
[0231]
[0232]
[0233]
[0234]
[0235]
[0236]
[0237]
[0238]
[0239]
DETAILED DESCRIPTION
[0240] As used herein the term “disintegrating oral tablet” is considered as a tablet for oral use. The oral tablet is considered as formed by tableting, i.e. compression of a particle composition, comprising the mentioned population of particles. Thus, the tablet is considered a compressed tablet formed by a plurality of particles. Particularly, the disintegrating oral tablet is designed such that it disintegrates upon mastication. Typically, the disintegrating oral tablet may also be referred to as oral tablet or merely tablet.
[0241] The term “weight of the oral tablet” or similar wording meaning the same is defined in the present context as weight of the oral tablet, not including the weight of an outer coating, such as a hard coating, soft coating, and the like.
[0242] By the phrase “texture” is meant a qualitative measure of the properties of the oral tablet and of the overall mouth-feel experienced by the user during use. Thus, the term “texture” encompasses measurable quantities such as hardness as well as more subjective parameters related to the feel experienced by a user.
[0243] The term “sustained release” or “extended release” is herein intended to mean prolonged release over time. The term “rapid release” or “quick release” or “high release” is herein intended to mean a higher content released for a given period of time. The term “controlled release” is intended to mean a release of a substance from an oral tablet by the aid of active use of the oral tablet in the oral cavity of the subject, whereby the active use is controlling the amount of substance released.
[0244] The verb “to comprise” as is used in this description and in the claims and its conjugations are used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements are present, unless the context clearly requires that there is one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”. Additionally, the words “a” and “an” when used in the present document in connection with the word comprising or containing denote “one or more.” The expression “one or more” is intended to mean one, two, three or more.
[0245] As used herein, the term “approximately” or “about” in reference to a number are generally taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value).
[0246] In the present context the phrase “population of particles” refers to a statistical population of particles. The population of particles may be characterized by a number of different parameters, e.g. statistical parameters such as distribution of particles, average particle size, particle size distribution width, etc. The population of particles may have subpopulations, such as DC sugar alcohol particles, non-DC sugar alcohol particles, or in some embodiments particles comprising gum base. The phrasing “population of particles” may in an embodiment of the invention be provided as a plurality of tableted particles and where the population of particles are tableted in one module or it may refer to a population of particles where some of the particles are tableted into one module and other particles are tableted into another module.
[0247] In the present context, the term “non-DC areas” refers to small volumes or spaces formed during tableting from the non-DC particles of non-DC sugar alcohol. Moreover, each of the non-DC areas may be composed of a single non-DC sugar alcohol particle, or may comprise several non-DC sugar alcohol particles. When the non-DC areas are distinct, i.e. not diffuse, the non-DC areas may be evenly distributed in the tablet, or at least one module thereof when the tablet comprises two or more modules. In such embodiments, where the non-DC areas are evenly distributed in in the tablet, or at least one module thereof, the non-DC areas may thus facilitate an even saliva generation in the mouth upon mastication.
[0248] The term “non-DC sugar alcohol particles” refer to particles of non-directly compressible (non-DC) sugar alcohol. It is noted that the terms “non-DC sugar alcohol particles” and “non-DC particles” are used interchangeably. In the present context, the non-DC sugar alcohol particles refer to particles which have not been preprocessed by granulation with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC). In the present context, non-DC sugar alcohol particles include particles obtained by crystallization followed by milling which does not involve other sugar alcohols or binders. Thus, non-DC sugar alcohol particles are considered as particles consisting of non-DC sugar alcohol.
[0249] The term “DC sugar alcohol particles” refer to particles of direct compressible (DC) sugar alcohol. It is noted that the terms “DC sugar alcohol particles” and “DC particles” are used interchangeably. DC sugar alcohol particles may be obtained e.g. as particles of sugar alcohols having DC grade by nature, e.g. sorbitol, or by granulating non-DC sugar alcohol with e.g. other sugar alcohols or binders for the purpose of obtaining so-called direct compressible particles (DC). Also, granulation of non-DC sugar alcohol with water as binder is considered to result in “DC sugar alcohol particles” in the present context.
[0250] In the present context when the non-DC areas are referred to as “discrete” this signifies that the non-DC sugar alcohols are not continuously distributed, but present in the discrete areas corresponding to the discrete nature of the non-DC sugar alcohol particles.
[0251] In the present context, the term “suitable for active pharmaceutical ingredients” refers to the tablet as a suitable vehicle for e.g. inclusion and delivery of active pharmaceutical ingredients. However, it is noted that the tablet may or may not include active pharmaceutical ingredients or active ingredients.
[0252] When referring to induced saliva generation, it is noted that this induced saliva generation exceeds any saliva generation without the use of the tablet of the invention. Particularly, in an embodiment the induced saliva generation exceeds saliva generation when using conventional tablets without non-DC areas. Then, induced saliva generation is increased over any saliva generation associated with conventional products, e.g. by comparing with a tablet without non-DC sugar alcohol particles, or with a tablet where the discrete areas are based on DC sugar alcohol particles.
[0253] When referring to induced saliva generation, the saliva generation is tested using the following method, unless stated otherwise.
[0254] Test subject abstain from eating and drinking at least 30 minutes before initiation of any test. Immediately before introducing of the tablet into the oral cavity, the test subject swallows. The test subject refrains from swallowing during the test. Immediately after introducing of the tablet into the oral cavity, the test subject starts masticating the tablet at a frequency of 1 chew per second for 20 seconds. Then, saliva and any remains of the tablet is kept in the mouth within chewing for 10 second. 30 seconds after starting the test, the test subject discards saliva including any tablet fragments into a plastic cup, which is weighted. Saliva discarded also at 90 seconds after onset of mastication, at 180 seconds after onset of mastication, at 300 seconds after onset of mastication, at 420 seconds after onset of mastication, and at 600 seconds after onset of mastication. At all times, the test subject makes as little movement as possible, and refrains from swallowing.
[0255] When referring to disintegration time, the following method is used throughout the application unless otherwise stated, unless stated otherwise.
[0256] Ten or more test subjects abstain from eating and drinking at least 30 minutes before initiation of any test. Immediately before introducing of the tablet into the oral cavity, the test subject swallows. The test subject refrains from swallowing during the test. Immediately after introducing of the tablet into the oral cavity, the test subject starts masticating the tablet at a frequency of 1 chew per second and stops mastication when the tablet is disintegrated. The time is noted and a visual validation of the disintegration is performed. The disintegration time is determined as a test panel average of the measured results.
[0257] As used herein, the term “orally disintegrating tablet” or “ODT” is intended to mean a tablet as understood by a skilled person within the art of ODT tablets, i.e. a solid dosage form that disintegrates rapidly (within seconds) without water when placed on the tongue.
[0258] As used herein, the term “particle size” refers to the average particle size as determined according to European Pharmacopoeia 9.1 when using test method 2.9.38 particle size distribution estimation by analytical sieving, unless otherwise specifically is mentioned.
[0259] The term “particle” or similar wording is intended to denote a single, discrete composition of solid matter, such as a granule or individual elements in powder, having a certain size that may deviate considerable.
[0260] As used herein the term “active ingredient” refers to a substance that is biologically active and has a physiological effect on the human body for the benefit of the human body or part thereof. Active ingredients include active pharmaceutical ingredients, but also other active substances such as nutraceuticals.
[0261] A “self-emulsifying agent” is an agent which will form an emulsion when presented with an alternate phase with a minimum energy requirement. In contrast, an emulsifying agent, as opposed to a self-emulsifying agent, is one requiring additional energy to form an emulsion.
[0262] In the present context, the term “disintegrate” refers to is a process where the tablet falls apart or disintegrates in to smaller aggregates and as defined by European Pharmacopeia 2.9.1 “Disintegration of tablets and capsules”. The time period of obtaining the desired disintegration, here less than 20 seconds.
[0263] In the present context the term “release” refers to the released substance being liberated from the water-soluble matrix. In some embodiments, the process of releasing a substance corresponds to the substance being dissolved in saliva. The term “release” in the present context is intended to mean tested under “in vivo” conditions, if not stated otherwise. In the present context, when the tablet is masticated, “in vivo” conditions is intended to mean that a samples is masticated with a chewing frequency of 60 chews pr. minute for a certain period of time in a test panel of 8 test persons, if not stated otherwise. These test persons abstain from eating and drinking at least 30 minutes before initiation of any test. The test persons are healthy persons appointed on an objective basis according to specified requirements.
[0264] In the present context the term “turn into liquid” is intended to mean that the tablet disintegrates and the fragments or particles of the tablet are either suspended or dissolved in saliva, perceived as liquid by a test person in accordance with the test procedure of induced saliva generation.
[0265] In the present context, “crunchiness”, “crunch”, “crunching” or similar expressions, when used in connection with testing of maximum resistance of a tablet, is intended to have the same meaning.
[0266] By the terms “water-insoluble gum base” or “gum base” or “gum base matrix” or similar wording is meant the mainly water-insoluble ingredients and hydrophobic gum base ingredients. The “gum base” may contain gum base polymers and plasticizers, waxes, emulsifiers, fats and/or fillers.
[0267] As used herein the term “pouch” is intended to mean a container typically formed by a web of a fibrous material enclosing a cavity. The pouch is designed for administration of an active ingredient in the oral cavity, and thus it is adapted for oral use, it is non-toxic and not water-soluble. The fibrous material may e.g. form a woven or non-woven web or fabric. The pouch may for example be sealed by bonding two corresponding pieces of web or fabric to each other along their edges to form a cavity for the active ingredient and the population of particles. In order to release the active ingredient, the pouch is made water-permeable so as to allow saliva from the oral cavity to penetrate the pouch and enter the cavity, where the saliva can come into contact with the active ingredient, whereby the active ingredient is released from the pouch.
[0268] In the following raw materials will refer to the mixed particles to be compressed into a tablet according to embodiments of the invention unless otherwise stated.
[0269] The following description outlines explanations of how the tablet of the invention may be produced and further details of what may be added to the inventive composition.
[0270] Typically, the process of manufacture of the inventive tablet may be performed in a single tablet press, such as a rotary tablet press. But it may be a benefit under some circumstances to apply a separate tablet press.
[0271] Preferably, the upper punch is convex which gives the upper face of the pressed tablet a concave form.
[0272] It should of course be noted that the shape of the punches may vary depending of the desired tablet shape.
[0273] In some embodiments of the invention, pressing of the tablets are performed at a force of 20 to 50 kN.
[0274] Important raw materials of the inventive tablet are non-DC sugar alcohol particles in combination with DC sugar alcohol particles.
[0275] The DC sugar alcohol particles refer to sugar alcohols known within the art as being direct compressible (DC).
[0276] The non-DC sugar alcohol particles refer to sugar alcohols known within the art as being non-directly compressible (DC).
[0277] According to a further embodiment of the invention, the applied non-DC sugar alcohol particles are best characterized as being non-directly compressible (non-DC). The use of non-DC sugar alcohols when compared to conventionally applied direct compressible sugar alcohol (DC) has shown remarkable effects to the user's perception of the delivery vehicle when chewed. This may partly be due to the somewhat larger size of non-DC sugar alcohol, when compared to DC sugar alcohol, but is may also be a result of a high content of sugar alcohol in the individual particles applied for compression. DC sugar alcohols, which for obvious reasons are marketed and applied for compression purposes, does not result in such improved salivation effect and mouthfeel.
[0278] It should be noted that the terminology non-DC is easily understood within the field of technology. Suppliers or sugar alcohol provides clear guidance to the user as for the ability for use in relation to compression of tablets. A non-DC particle in this connection is referred to as a particle which is not expressly recommended by the supplier for compression. Examples of a non-DC grade of erythritol includes Zerose (TM) erythritol 16952F supplied by Cargill. Further examples of non-DC sugar alcohol particles include non-DC xylitol as Xivia C from Dupont, non-DC isomalt as Iomalt GS from Beneo Paltinit, non-DC mannitol as Pearlitol from Roquette, non DC maltitol as Maltisorb. P200 from Roquette. Examples of a direct compressible (DC) grade of erythritol include Zerose™ DC 16966 also supplied by Cargill. Further examples of DC sugar alcohols include sorbitol particles provided as e.g. Neosorb (ID P 300 DC from Roquette, mannitol particles provided as e.g. Pearlitol® 300DC or Pearlitol 200 SD from Roquette, maltitol provided as e.g. SweetPearl® P 300 DC, xylitol provided as e.g. Xylisorb® 200 DC or Xylitab from Dupont.
[0279] Non-direct compressible (non-DC) sugar alcohols may include non-DC grades of Xylitol, non-DC grades of Erythritol, non-DC grades of Mannitol, non-DC grades of maltitol, non-DC grades of Lactitol, non-DC grades of Isomalt, or other suitable non-DC grades of sugar alcohols.
[0280] Direct compressible (DC) sugar alcohols may include sorbitol which is DC by nature, DC grades of Xylitol, DC grades of Erythritol, DC grades of Mannitol, DC grades of maltitol, DC grades of Lactitol, Isomalt or other suitable DC grades of sugar alcohols.
[0281] The present invention benefits from a synergy between the non-DC sugar alcohol particles and the DC sugar alcohol particles. The DC sugar alcohols may be e.g. sorbitol which is direct compressible by nature or it may be other sugar alcohols which has been preprocessed, e.g. by granulation with a suitable binder, to obtain particles which when compressed may encapsulate the non-DC sugar alcohol particles into a mechanically stable tablet. At the same time the non-DC sugar alcohol particles serves as a means for salivation which is both attractive to the user and also serves for the purpose of dissolving the DC sugar alcohol particles when the tablet is chewed as fast as possible.
[0282] According to embodiments of the invention, encapsulated flavors or active ingredients may be added to the final blend of raw materials prior to compression.
[0283] Different methods of encapsulating flavors or active ingredients, which may both refer to flavors or active ingredients mixed into the raw materials to be compressed into the chewing gum may e.g. include spray drying, spray cooling, film coating, coascervation, Double emulsion method (Extrusion technology) or prilling.
[0284] Materials to be used for the above-mentioned encapsulation methods may e.g. include Gelatine, Wheat protein, Soya protein, Sodium caseinate, Caseine, Gum arabic, Mod. starch, Hydrolyzed starches (maltodextrines), Alginates, Pectin, Carregeenan, Xanthan gum, Locus bean gum, Chitosan, Bees wax, Candelilla wax, Carnauba wax, Hydrogenated vegetable oils, Zein and/or Sucrose.
[0285] Preferably, these ingredients should be added subsequent to any significant heating or mixing. In other words, the active ingredients should preferably be added immediately prior to the compression of the final tablet.
[0286] If applying the present invention in relation to chewing gum, the adding of active ingredients may be cautiously blended with pre-mixed gum base granulates and further ingredients such as the ingredients stipulated by the present claims, immediately prior to the final compression of the tablet.
[0287] For those active ingredients listed below, it should be noted that they are optional in the present invention unless specifically stated.
[0288] In one embodiment the tablet according to the invention comprises a pharmaceutically, cosmetically or biologically active substance. Examples of such active substances, a comprehensive list of which is found e.g. in WO 00/25598, which is incorporated herein by reference, include drugs, dietary supplements, antiseptic agents, pH adjusting agents, anti-smoking agents and substances for the care or treatment of the oral cavity and the teeth such as hydrogen peroxide and compounds capable of releasing urea during chewing. Examples of useful active substances in the form of antiseptics include salts and derivatives of guanidine and biguanidine (for instance chlorhexidine diacetate) and the following types of substances with limited water-solubility: quaternary ammonium compounds (e.g. ceramine, chloroxylenol, crystal violet, chloramine), aldehydes (e.g. paraformaldehyde), derivatives of dequaline, polynoxyline, phenols (e.g. thymol, p-chlorophenol, cresol), hexachlorophene, salicylic anilide compounds, triclosan, halogenes (iodine, iodophores, chloroamine, dichlorocyanuric acid salts), alcohols (3,4 dichlorobenzyl alcohol, benzyl alcohol, phenoxyethanol, phenylethanol), cf. also Martindale, The Extra Pharmacopoeia, 28th edition, pages 547-578; metal salts, complexes and compounds with limited water-solubility, such as aluminum salts, (for instance aluminum potassium sulphate AlK(SO4)2, 12H2O) and salts, complexes and compounds of boron, barium, strontium, iron, calcium, zinc, (zinc acetate, zinc chloride, zinc gluconate), copper (copper chloride, copper sulphate), lead, silver, magnesium, sodium, potassium, lithium, molybdenum, vanadium should be included; other compositions for the care of mouth and teeth: for instance; salts, complexes and compounds containing fluorine (such as sodium fluoride, sodium monofluorophosphate, aminofluorides, stannous fluoride), phosphates, carbonates and selenium. Further active substances can be found in J. Dent. Res. Vol. 28 No. 2, pages 160-171, 1949.
[0289] Examples of active substances in the form of agents adjusting the pH in the oral cavity include: acids, such as adipic acid, succinic acid, fumaric acid, or salts thereof or salts of citric acid, tartaric acid, malic acid, acetic acid, lactic acid, phosphoric acid and glutaric acid and acceptable bases, such as carbonates, hydrogen carbonates, phosphates, sulphates or oxides of sodium, potassium, ammonium, magnesium or calcium, especially magnesium and calcium.
[0290] Active ingredients may comprise the below mentioned compounds or derivates thereof but are not limited thereto: Acetaminophen, Acetylsalicylic acid, Buprenorphine, Bromhexin, Celcoxib, Codeine, Diphenhydramin, Diclofenac, Etoricoxib, Ibuprofen, Indometacin, Ketoprofen, Lumiracoxib, Morphine, Naproxen, Oxycodon, Parecoxib, Piroxicam, Pseudoefedrin, Rofecoxib, Tenoxicam, Tramadol, Valdecoxib, Calciumcarbonat, Magaldrate, Disulfiram, Bupropion, Nicotine, Azithromycin, Clarithromycin, Clotrimazole, Erythromycin, Tetracycline, Granisetron, Ondansetron, Prometazin, Tropisetron, Brompheniramine, Ceterizin, leco-Ceterizin, Chlorcyclizine, Chlorpheniramin, Chlorpheniramin, Difenhydramine, Doxylamine, Fenofenadin, Guaifenesin, Loratidin, des-Loratidin, Phenyltoloxamine, Promethazin, Pyridamine, Terfenadin, Troxerutin, Methyldopa, Methylphenidate, Benzalcon. Chloride, Benzeth. Chloride, Cetylpyrid. Chloride, Chlorhexidine, Ecabet-sodium, Haloperidol, Allopurinol, Colchinine, Theophylline, Propanolol, Prednisolone, Prednisone, Fluoride, Urea, Actot, Glibenclamide, Glipizide, Metformin, Miglitol, Repaglinide, Rosiglitazone, Apomorfin, Cialis, Sildenafil, Vardenafil, Diphenoxylate, Simethicone, Cimetidine, Famotidine, Ranitidine, Ratinidine, cetrizin, Loratadine, Aspirin, Benzocaine, Dextrometorphan, Phenylpropanolamine, Pseudoephedrine, Cisapride, Domperidone, Metoclopramide, Acyclovir, Dioctylsulfosucc., Phenolphtalein, Almotriptan, Eletriptan, Ergotamine, Migea, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan, Aluminum salts, Calcium salts, Ferro salts, Ag-salts, Zinc-salts, Amphotericin B, Chlorhexidine, Miconazole, Triamcinolonacetonid, Melatonine, Phenobarbitol, Caffeine, Benzodiazepiner, Hydroxyzine, Meprobamate, Phenothiazine, Buclizine, Brometazine, Cinnarizine, Cyclizine, Difenhydramine, Dimenhydrinate, Buflomedil, Amphetamine, Caffeine, Ephedrine, Orlistat, Phenylephedrine, Phenylpropanolamin, Pseudoephedrine, Sibutramin, Ketoconazole, Nitroglycerin, Nystatin, Progesterone, Testosterone, Vitamin B12, Vitamin C, Vitamin A, Vitamin D, Vitamin E, Pilocarpin, Aluminumaminoacetat, Cimetidine, Esomeprazole, Famotidine, Lansoprazole, Magnesiumoxide, Nizatide and or Ratinidine.
[0291] The invention is suitable for increased or accelerated release of active agents selected among the group of dietary supplements, oral and dental compositions, antiseptic agents, pH adjusting agents, anti-smoking agents, sweeteners, flavorings, aroma agents or drugs. Some of those will be described below.
[0292] The active agents to be used in connection with the present invention may be any substance desired to be released from the tablet. The active agents, for which a controlled and/or accelerated rate of release is desired, are primarily substances with a limited water-solubility, typically below 10 g/100 mL inclusive of substances which are totally water-insoluble. Examples are medicines, dietary supplements, oral compositions, anti-smoking agents, highly potent sweeteners, pH adjusting agents, flavorings etc.
[0293] Other active ingredients are, for instance, paracetamol, benzocaine, cinnarizine, menthol, carvone, caffeine, chlorhexidine-di-acetate, cyclizine hydrochloride, 1,8-cineol, nandrolone, miconazole, mystatine, sodium fluoride, nicotine, cetylpyridinium chloride, other quaternary ammonium compounds, vitamin E, vitamin A, vitamin D, glibenclamide or derivatives thereof, progesterone, acetylsalicylic acid, dimenhydrinate, cyclizine, metronidazole, sodium hydrogen carbonate, the active components from ginkgo, the active components from propolis, the active components from ginseng, methadone, oil of peppermint, salicylamide, hydrocortisone or astemizole.
[0294] Examples of active agents in the form of dietary supplements are for instance salts and compounds having the nutritive effect of vitamin B2 (riboflavin), B12, folinic acid, folic acid, niacine, biotine, poorly soluble glycerophosphates, amino acids, the vitamins A, D, E and K, minerals in the form of salts, complexes and compounds containing calcium, phosphorus, magnesium, iron, zinc, copper, iodine, manganese, chromium, selenium, molybdenum, potassium, sodium or cobalt.
[0295] Furthermore, reference is made to lists of nutritionists accepted by the authorities in different countries such as for instance US code of Federal Regulations, Title 21, Section 182.5013.182 5997 and 182.8013-182.8997.
[0296] Examples of active agents in the form of antiseptics are for instance salts and compounds of guanidine and biguanidine (for instance chlorhexidine diacetate) and the following types of substances with limited water-solubility: quaternary ammonium compounds (for instance ceramine, chloroxylenol, crystal violet, chloramine), aldehydes (for instance paraformaldehyde), compounds of dequaline, polynoxyline, phenols (for instance thymol, para chlorophenol, cresol) hexachlorophene, salicylic anilide compounds, triclosan, halogenes (iodine, iodophores, chloroamine, dichlorocyanuric acid salts), alcohols (3,4 dichlorobenzyl alcohol, benzyl alcohol, phenoxyethanol, phenylethanol), cf. furthermore Martindale, The Extra Pharmacopoeia, 28th edition, pages 547-578; metal salts, complexes and compounds with limited water-solubility, such as aluminum salts, (for instance aluminum potassium sulphate AlK(SO4)2, 12H2O) and furthermore salts, complexes and compounds of boron, barium, strontium, iron, calcium, zinc, (zinc acetate, zinc chloride, zinc gluconate), copper (copper chloride, copper sulfate), lead, silver, magnesium, sodium, potassium, lithium, molybdenum, vanadium should be included; other compositions for the care of mouth and teeth: for instance; salts, complexes and compounds containing fluorine (such as sodium fluoride, sodiummonofluorophosphate, amino fluorides, stannous fluoride), phosphates, carbonates and selenium.
[0297] Cf. furthermore J. Dent.Res. Vol. 28 No. 2, pages 160-171, 1949, wherein a wide range of tested compounds is mentioned.
[0298] Examples of active agents in the form of agents adjusting the pH in the oral cavity include for instance: acceptable acids, such as adipic acid, succinic acid, fumaric acid, or salts thereof or salts of citric acid, tartaric acid, malic acid, acetic acid, lactic acid, phosphoric acid and glutaric acid and acceptable bases, such as carbonates, hydrogen carbonates, phosphates, sulfates or oxides of sodium, potassium, ammonium, magnesium or calcium, especially magnesium and calcium.
[0299] Examples of active agents in the form of anti-smoking agents include for instance: nicotine, tobacco powder or silver salts, for instance silver acetate, silver carbonate and silver nitrate.
[0300] Further examples of active agents are medicines of any type.
[0301] Examples of active agents in the form of medicines include caffeine, salicylic acid, salicyl amide and related substances (acetylsalicylic acid, choline salicylate, magnesium salicylate, sodium salicylate), paracetamol, salts of pentazocine (pentazocine hydrochloride and pentazocinelactate), buprenorphine hydrochloride, codeine hydrochloride and codeine phosphate, morphine and morphine salts (hydrochloride, sulfate, tartrate), methadone hydrochloride, ketobemidone and salts of ketobemidone (hydrochloride), beta-blockers, (propranolol), calcium antagonists, verapamil hydrochloride, nifedinpine as well as suitable substances and salts thereof mentioned in Pharm. Int., November 85, pages 267-271, Barney H. Hunter and Robert L. Talbert, nitroglycerine, erythrityl tetranitrate, strychnine and salts thereof, lidocaine, tetracaine hydrochloride, etorphine hydrochloride, atropine, insulin, enzymes (for instance papain, trypsin, amyloglucosidase, glucoseoxidase, streptokinase, streptodornase, dextranase, alpha amylase), polypeptides (oxytocin, gonadorelin, (LH.RH), desmopressin acetate (DDAVP), isoxsuprine hydrochloride, ergotamine compounds, chloroquine (phosphate, sulfate), isosorbide, demoxytocin, heparin.
[0302] Other active ingredients include beta-lupeol, Letigen®, Sildenafil citrate and derivatives thereof.
[0303] Further examples of active ingredients include dental products including Carbamide, CPP Caseine Phospho Peptide; Chlorhexidine, Chlorhexidine di acetate, Chlorhexidine Chloride, Chlorhexidine di gluconate, Hexetedine, Strontium chloride, Potassium Chloride, Sodium bicarbonate, Sodium carbonate, Fluor containing ingredients, Fluorides, Sodium fluoride, Aluminum fluoride.
[0304] Further examples of active ingredients include Ammonium fluoride, Calcium fluoride, Stannous fluoride, Other fluor containing ingredients Ammonium fluorosilicate, Potassium fluorosilicate, Sodium fluorosilicate, Ammonium monofluorphosphate, Calcium monofluorphosphate, Potassium monofluorphosphate, Sodium monofluorphosphate, Octadecentyl Ammonium fluoride, Stearyl Trihydroxyethyl Propylenediamine Dihydrofluoride
[0305] Further examples of active ingredients include vitamins. Vitamins include A, B1, B2, B6, B12, Folinic acid, Folic acid, niacin, Pantothenic acid, biotine, C, D, E, K. Minerals include Calcium, phosphor, magnesium, iron, Zinc, Copper, Iod, Mangan, Crom, Selene, Molybden. Other active ingredients include:
Q10®, enzymes. Natural drugs including Ginkgo Biloba, ginger, and fish oil.
[0306] Further examples of active ingredients include migraine drugs such as Serotonin antagonists: Sumatriptan, Zolmitriptan, Naratriptan, Rizatriptan, Eletriptan; nausea drugs such as Cyclizin, Cinnarizin, Dimenhydramin, Difenhydrinat; hay fever drugs such as Cetrizin, Loratidin, pain relief drugs such as Buprenorfin, Tramadol, oral disease drugs such as Miconazol, Amphotericin B, Triamcinolonaceton; and the drugs Cisaprid, Domperidon, Metoclopramid. In a preferred embodiment the invention relates to the release of Nicotine and its salts.
[0307] In an advantageous embodiment of the invention the active ingredient is selected from active ingredients for the throat selected from acetylcysteine, ambroxol, amylmetacresol, benzocaine, bisacodyl, bismuth sub salicylate, bromhexine, cetirizine, cetylpyridinium, chlorhexidine, dextromethorphan hydrobromide, 2,4-dichlorobenzyl alcohol, doxylamine succinate, eucalyptus oil, flurbiprofen, glycerin, hexylresorcinol, lidocaine, menthol, myrrh, paracetamol, pectin, peppermint oil, phenol, phenylephrine, povidone-iodine, pseudoephedrine, ranitidine, simethicone, sodium docusate, spearmint, zinc, or any combination thereof; active ingredients for the gastrointestinal tract selected from alginate, atenolol, aspirin (acetylsalicylic acid), ampicillin, aminosalicylates, anhydrous citric acid, aspirin, bisacodyl, bismuth subsalicylate, bupropion, caffeine, calcium, calcium carbonate, cetirizine, cimetidine, cisapride, clarithromycin, desloratadine, dexlansoprazole, diphenhydramine HCl, diphenhydramine citrate, dimenhydrinate, docusate erythromycin, dopamine, esomeprazole, famotidine, fexofenadine HCl, guaifenesin, hydrotalcite, ibuprofen, ketoprofen, lactase enzyme, lansoprazole, loratadine, lorcaserin, loperamide, loperamide HCl, magnesium, magnesium carbonate, magnesium hydroxide, melatonin, methamphetamine HCl, metoclopramide, metronidazole, montelukast, mycostatin, naltrexone, naproxen, naproxen sodium, nizatidine, omeprazole, ondansetron, orlistat, pantoprazole, paracetamol (acetaminophen), pectin, phentermine HCl, polypodium leucotomos, prednisolone, prednisone, progesterone, propranolol, propantheline bromide, pseudoephedrine HCl, phentermine, rabeprazole, ranitidine, roflumilast, scopoloamine butyl hydroxide, simethicone, sodium, sodium bicarbonate, sodium docusate, sumatriptan, testosterone, tetracycline, topiramate, vitamin A, vitamin B, vitamin B12, vitamin C (ascorbic acid), vitamin D, and vitamin E, vitamin K, or any combination thereof, and active ingredients for buccal absorption selected from atenolol, baclofen, caffeine, carvedilol, chlorpheniramine, chlorpheniramine maleate, fluticasone propionate, maleate, desmopressin, diltiazem hydrochloride, doxylamine succinate, mycostatin, nicotine, nifedipine, nitroglycerin, omeprazole, ondansetron, oxymetazoline HCl, oxytocin, phenylephrine, piroxicam, prednisone, propranolol, salbutamol sulphate, scopoloamine butyl hydroxide, sumatriptan, triamcinolonacetonid, and any combination thereof.
[0308] When including gum base in the formulation sugar alcohols typically constitute from about 5 to about 95% by weight of the tablet, more typically about 20 to about 80% by weight such as 30 to 70% or 30 to 60% by weight of the tablet.
[0309] In such an embodiment of the invention, the tablet further comprises, beside the already described sugar alcohols, materials selected from the group consisting of bulk sweeteners, flavors, dry-binders, tableting aids, anti-caking agents, emulsifiers, antioxidants, enhancers, absorption enhancers, buffers, high intensity sweeteners, softeners, colors, or any combination thereof.
[0310] Suitable sugar alcohols typically constitute from about 40 to about 99.9% by weight of the tablet, such as about 80 to about 99% by weight of the tablet.
[0311] High intensity artificial sweetening agents can also be used alone or in combination with the above sweeteners. Preferred high intensity sweeteners include, but are not limited to sucralose, aspartame, salts of acesulfame, alitame, saccharin and its salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcones, thaumatin, monellin, stevioside (natural intensity sweetener) and the like, alone or in combination. In order to provide longer lasting sweetness and flavor perception, it may be desirable to encapsulate or otherwise control the release of at least a portion of the artificial sweeteners. Techniques such as wet granulation, wax granulation, spray drying, spray chilling, fluid bed coating, conservation, encapsulation in yeast cells and fiber extrusion may be used to achieve desired release characteristics. Encapsulation of sweetening agents can also be provided using another tablet component such as a resinous compound.
[0312] Usage level of the artificial sweetener will vary considerably and will depend on factors such as potency of the sweetener, rate of release, desired sweetness of the product, level and type of flavor used and cost considerations. Thus, the active level of artificial sweetener may vary from about 0.001 to about 8% by weight (preferably from about 0.02 to about 8% by weight). When carriers used for encapsulation are included, the usage level of the encapsulated sweetener will be proportionately higher. Combinations of sugar and/or non-sugar sweeteners may be used in the tablet formulation.
[0313] A tablet according to the invention may, if desired, include one or more fillers/texturisers including as examples, magnesium and calcium carbonate, sodium sulphate, ground limestone, silicate compounds such as magnesium and aluminum silicate, kaolin and clay, aluminum oxide, silicium oxide, talc, titanium oxide, mono-, di- and tri-calcium phosphates, cellulose polymers and combinations thereof.
[0314]
[0315] The composition and the way the tablet is or can be made is described elsewhere in the application and details regarding the structure and functioning of this tablet 10 is also indicated and explained further with reference to
[0316]
[0317] The composition and the way the tablet is made is described elsewhere in the application.
[0318] Details regarding the structure and functioning of this tablet 10 is also indicated and explained further with reference to
[0319] The intention with this illustration is to give an example of a physical form, which may be applicable within the scope of the invention. The intention is also to illustrate how the term “a module” is understood and applied throughout the description, i.e. that a module is referring to a population of a plurality particles and the particles have been tableted together to form a module. The term module is applied to indicate that one module comprises one population of tableted particles and another module comprises another population of tabled particles. A population of particles in the present context is thus understood to refer to a plurality of particles. A singular particle is thus of course not understood as a module.
[0320] Modules are typically, but not necessarily, distinguishable by the human eye, in particular if the applied compounds in the different modules are formed by differently colored population of particles or mixtures of particles.
[0321] The oral tablet 20 comprises an upper module 21 and a lower module 22. The modules, here in the shapes of layers, are thus physically distinct and each comprises a population of particles which has been tableted. The population of the different modules, 21 and 22, may typically be different for many purposes. Examples include use for visual conception, for mechanical purposes e.g. providing strength, for medical purposes, and of course also for maximizing the desired effect of non-DC sugar alcohol contained in the tablet.
[0322] In a preferred embodiment, most of the applied non-DC sugar alcohol(s) is comprised in the upper module 21 and the lower module 22 is mostly comprised of DC-components, i.e. components such as sugar alcohols, fillers, flavors, colors etc. conventionally used for direct compression. In embodiments of the invention, a first module, here the lower module 22 may be regarded and applied as a support module supporting another module, here the upper module 21. The benefit of this division in the designing of properties is that the module containing the non-DC sugar alcohol particles may comprises substantial amounts of non-DC sugar alcohol particles even in spite of the fact that the modules own mechanical strength is substantially weakened, as the supporting modules structural strength may be designed to ensure that the overall structural strength of the tablet is sufficient to obtain the desired friability and tablet appearance. This multi-modular design approach is of even more interest as the tablets designed according to this principle benefits, in terms of disintegration and dissolving of the tablet matrix during mastication of the tablet, from the increased salivation effect obtained from the applied high content of non-DC sugar alcohol particles in the relatively weak module.
[0323]
[0324] The illustrated tablet 30 comprises an upper module 31, and intermediate module 33 and a lower module 32.
[0325] The upper module 31 may, as explained in relation to the upper module of
[0326] The lower module 32 may comprise substantial amounts of DC-particles such as sugar alcohol(s), fillers, some binder and other relevant ingredients enabling the lower module 32 to form a structural support for at least the upper module 31.
[0327]
[0328] Such part 40 of a tablet may within the scope of the invention comprise at least two different types of particles, namely non-DC sugar alcohol particles 41 and DC-particles 42. Preferred but non-limiting non-DC sugar alcohols are non-DC erythritol and non-DC xylitol as these non-DC sugar alcohols have shown effective to obtain the desired effect. The illustrated non-DC particles 41, although indicated on the figures with the same graphical expression may of course comprise non-DC sugar alcohol particles of the same type, but also comprise a mixture of two or more non-DC sugar alcohol particles.
[0329] The particles are evenly distributed amongst a plurality of DC particles 42 within the specified module. The DC particles 42, although indicated in the figure as same type particles may include different types of DC sugar alcohol particles, flavor particles, binders, etc. The intention with the figure is to illustrate that the non-DC sugar alcohol particles 41 in practice have to be homogenously distributed amongst the DC particles 42 in the final oral tablet 40. It may not be enough that the non-DC particles and DC particles are mixed homogenously at some stage during the preparation of the tableting process. The homogenous mix should preferably be maintained in the final oral tablet 40 in order to promote the desired effect and to obtain a mechanically stable tablet. A further advantageous effect of the evenly distributed non-DC sugar alcohol particles may be obtained through an advantageous and increased salivation during mastication of a tablet.
[0330] The understanding and conception of the evenly distribution of the non-DC sugar alcohol particles in the relevant tablet module may in practical terms be very difficult to define as such definitions are very difficult to monitor and control during the processing of the tablet but it has been possible to establish an industrial scale process, where the mixture containing the substantial amounts of non-DC sugar alcohol(s) may be established all the way through the process into the final tablet. Such process may e.g. be validated by test manufacturing of a sequence of tablets where the variation of the non-DC sugar alcohol content of the manufactured tablets are determined.
[0331] It is noted that the non-DC particles 41 forms small sub-areas or sub spaces in the final oral tablet or the relevant module of the final tablet, e.g. the upper modules 21 and 31. These sub-areas are elsewhere in the present application referred to as discrete non-DC areas and may be formed by single non-DC particles or very small groups of these non-DC particles. These discrete non-DC areas are thus intended to be contained within a matrix formed by DC-sugar alcohol particles or other DC-particles.
[0332] The non-DC areas, in the present embodiment, the non-DC sugar alcohol particles 41 are thus included in substantial amounts in the tablet and from a mechanical perspective supported and contained by the DC-particles 42 and together forming a matrix which, when chewed, may bring the non-DC sugar alcohol particles 41 into contact with the oral cavity and promote salivation. The promoted salivation, together with relatively weak mechanical structure of the module or tablet comprising the non-DC sugar alcohol particles induces a fast breakup of the tablet and thereby pushes the non-DC particles into contact with the oral cavity in a way which is completely different from compressed tablets made from DC-sugar alcohol particles, such as granulated erythritol or xylitol.
[0333] The non-DC areas may thus result in induced saliva generation upon mastication of the tablet and also induce and promote a very fast and pleasant dissolving of the tablet matrix when compared to conventional compressed tablets.
[0334] Active ingredients may be present as both DC and non-DC particles as long as the active ingredient as such does not interfere significant with other compounds. If the active ingredients are non-DC particles, the amount should be kept low enough to ensure the mechanical stability of the tablet or modules or alternatively compensated by relevant DC-particles or binders. It should be noted that such a compensation should be carefully considered as this compensation may both compromise salivation effect and texture/mouthfeel during mastication.
[0335]
[0336] In terms of components applied, the tablet part illustrated in
[0337] The intention with the present
[0338]
[0339] Again, in relation to
[0340] Particles comprising gum base, may also be present both as non-DC and DC particles, although DC-particles comprising gum base are highly preferred over non-DC gum base-containing particles. When applying particles comprising gum base, these particles are preferably but not necessarily included in a supporting module as DC particles 63 e.g. with mixed with sugar alcohol particles 63 as illustrated in
[0341] The above illustrated modules are all designed as layers. It is stressed that other shapes of modules may be applicable within the scope of the invention. Non-limiting examples are modules having a sphere shape, diamond shape, oval shape, cone shape, etc. All the relevant shapes must of course be adapted to fit the tableting process according to known measures within the art.
EXAMPLES
Examples 1-38. Preparation of Two-Layer Tablets
[0342]
TABLE-US-00001 TABLE 1A Oral tablet compositions for first layer of bi-layer tablets containing flavor. Amounts are given in wt-% of the respective layer of the tablet. Raw material (wt %) First layer Ex1 Ex2 Ex3 Ex4 Ex5 Ex6 Non-DC 50 — — — — — Xylitol Sorbitol** — 50 — — — — Non-DC — — 50 — — — Isomalt Non-DC — — — 50 — — Erythritol Non-DC — — — — 50 — Mannitol Non-DC — — — — — 50 Maltitol DC Isomalt 43.75 43.75 43.75 43.75 43.75 43.75 Flavor 4 4 4 4 4 4 HIS 0.25 0.25 0.25 0.25 0.25 0.25 Magnesium 1 1 1 1 1 1 Stearate Binder HPC 1 1 1 1 1 1 Resistance 160 >350 190 142 90 174 to crunch [N]* Friability 0.74 0.25 0.63 1.30 1.45 1.00 *Method limitation means maximum resistance to crunch which can be measured up to 350N. **non-granulated sorbitol.
TABLE-US-00002 TABLE 1B Oral tablet compositions for first layer of bi-layer tablets containing flavor. Amounts are given in wt-% of the respective layer of the tablet. Raw material (wt %) First layer Ex7 Ex8 Ex9 Ex10 Ex11 Ex12 Non-DC 50 — — — — — Xylitol Sorbitol** — 50 — — — — Non-DC — — 50 — — — Isomalt Non-DC — — — 50 — — Erythritol Non-DC — — — — 50 — Mannitol Non-DC — — — — — 50 Maltitol Sorbitol 44.25 44.25 44.25 44.25 44.25 44.25 Flavor 4 4 4 4 4 4 HIS 0.25 0.25 0.25 0.25 0.25 0.25 Magnesium 1 1 1 1 1 1 Stearate Binder HPC 0.5 0.5 0.5 0.5 0.5 0.5 Resistance 190 >350 270 170 120 210 to crunch [N]* Friability 0.65 0.12 0.87 1.13 1.25 0.88 *Method limitation means maximum resistance to crunch which can be measured up to 350N. **non-granulated sorbitol.
TABLE-US-00003 TABLE 2 Oral tablet compositions for the second layer of bi-layered tablets containing flavor. Amounts are given in wt-% of the respective layer of the tablet. Rw material (wt %) Second layer Ex1-12 Ex13-24 Ex25-36 DC Maltitol 94.75 — — DC Xylitol — 94.75 — DC Isomalt — — 94.75 Flavor 4 4 4 HIS 0.25 0.25 0.25 Magnesium 1 1 1 Stearate
TABLE-US-00004 TABLE 3 Oral tablet compositions for bi-layered tablets containing flavor. Amounts are given in wt-% of the respective layer of the tablet. Ex 37 Ex 38 Raw material (wt %) First layer Non-DC Erythritol 50 50 DC Isomalt 43.75 43.75 Flavor 4 4 HIS 0.25 0.25 Magnesium 1 1 Stearate Binder HPC 1 1 Raw material (wt %) Second layer DC Erythritol 94.75 — DC Mannitol — 94.75 Flavor 4 4 HIS 0.25 0.25 Magnesium 1 1 Stearate Resistance to 140 182 crunch [N]* Friability 1.25 1.68 *Method limitation means maximum resistance to crunch which can be measured up to 350N.
Process Flow
[0343] The compositions indicated in the above Tables 1A and 1B and 2 are each processed into two-layer tablets with compositions as outlined in examples 1-12, 13-24 and 25-36. In other words, the examples 1-12 are bi-layer tablet with a first layer according to Table 1A and 1B and the second layer is based primarily on DC maltitol. In examples 13-24, the second layer is primarily based on DC Xylitol. In examples 25-36, the second layer is primarily based on DC isomalt as shown in Table 2.
[0344] The composition of Table 3 is likewise processed into corresponding two-layer tablets of each of the compositions as indicated examples 37 and 38.
[0345] For each example 1-38 the raw materials are sieved with a 1600 micron sieve and then weighed into the proper amount according to the exampled compositions of Tables 1A to 3.
[0346] The weighed amounts are then added to a Turbula mixer in a stainless-steel container and blended at 50 rpm for 5 minutes. MgSt was added after 4 minutes of blending.
[0347] The mixtures are then tableted by means of a Piccola RIVA DC-SC-041-2 or a Fette 3090i.
[0348] The applied molds have circular cross sections with diameters of 16 mm and are hollowed to produce tablets, which are concave and/or curved. Evidently, other mold size and shapes may be applied within the scope of the invention.
[0349] The resulting tablets according to Examples 1-38 are then obtained by tableting with a suitable pressure force.
[0350] For each tablet of examples 1-38, the second layer as outlined in Table 2 and referred to as the second layer in Table 3 is pressed initially at a first relatively low pressure.
[0351] The blended composition of the so-called first layer, i.e. compositions of Tables 1A and 1B and the first layer of Table 3 is then fed to the mold and a final two-layer tablet is then compressed at higher pressure than the pressure applied on the first layers, thereby producing final two-layer tablets according to Examples 1-38. It is noted that the final two-layer tablets of examples 1-38 are 1.8 grams tablets and that the first layer of the tablets weighs 0.9 and the second layer of the tablets weighs 0.9 gram.
[0352] A specification of relevant compounds applied in the examples explained above are listed below.
HPC: Hydroxy propyl cellulose. Klucel Nutra D from Ashland
Non-DC Xylitol: Xivia C from Dupont
Non-granulated Sorbitol from PharmSorbidex from Cargill
Non-DC Isomalt: Isomalt GS from Beneo Paltinit
Non-DC Mannitol: Pearlitol from Roquette
Non-DC Maltitol: Maltisorb. P200 from Roquette
Non-DC Erythritol: Zerose 16952 from Cargill
DC Erythritol—Zerose 16966 from Cargill
DC Xylitol—Xylitab 200 from Dupont
DC Isomalt—Isomalt DC 101 from Beneo Paltinit
DC Mannitol—Pearlitol SD200 from Roquette
DC Maltitol—Sweetpearl 300 DC from Roquette
Examples 39-41
[0353]
TABLE-US-00005 TABLE 3B Compositions for 1.8 gram oral tablets. Amounts are given in wt-% of the tablet. Rw material (wt %) l layer Ex39 Ex40 Ex41 DC Isomalt 45 35 — Non-DC Erythritol 48.75 43.75 48.75 DC CaCO3 — 15 45 Flavor 4 4 4 HIS 0.25 0.25 0.25 Magnesium 1 1 1 Stearate Binder HPC 1 1 1
All ingredients were received in powder form.
DC Isomalt—Isomalt DC 101 from Beneo Paltinit
Non-DC Erythritol: Zerose 16952 from Cargill
HPC: Hydroxy propyl cellulose. Klucel Nutra D from Ashland
DC CaCO3: Scoralite 97 PVP from Scora
Process Flow
[0354] For each of the examples 39-41 the raw materials are sieved with a 1600 micron sieve and then weighed into the proper amount according to the exampled compositions of Table 3B.
[0355] For each example the weighed amounts are then added to a Turbula mixer in a stainless-steel container and blended at 50 rpm for 4 minutes and then adding magnesium stearate and blending one additional minute.
[0356] The resulting tablets according to Examples 39-41 are then obtained by tableting the mixtures by means of a Piccola RIVA DC-SC-041-2. A Fette 3090i may also applied.
Evaluation
[0357]
TABLE-US-00006 TABLE 3C Sensory evaluation of Examples 13-18. Initial Total sensory Watering experience effect Good/ Suitable 1-5 Acceptable Fast dissolving 1 low Ex (Acc)/Poor Chewable tablet 5 high 13 Acc A bit hard initial chew, disintegrate 4 with crunchy feeling, many big particles for a long time 14 Poor Unacceptable hard chew-not 2 chewable or complete dissolvable within the first 30 seconds. 15 Poor Very hard and difficult to 3 disintegrate. Saliva increases but with many big non-dissolved particles though the first 30 sec. 16 Good Nice crunchy fast dissolving tablet 5 17 Poor Soft initial chew, different mouth 2 feel. Sticky feeling. Does not dissolve fast enough or provide pleasant watering effect 18 Poor Hard initial chew. Very crumble and 4 sandy feeling. Salivation generation but sandy liquid feeling
[0358] The above two-layer Examples 13-18 were evaluated according to three parameters by a test panel.
[0359] Two of the parameters were suitability as a chewable tablet and one parameter was the perceived watering effect. Due to the more complex nature of a two-layer tablet two further parameters were evaluated, namely resistance to crunch and friability.
[0360] It was first of all noted that the watering effect was considered relatively high for examples 13, 15, 16 and 18, i.e. the examples based on non-DC Xylitol, non-DC Isomalt, non-DC Erythritol and non-DC Maltitol. The watering effect is considered to be representative or equal to the elsewhere described salivation effect.
[0361] The test panel clearly indicated that the overall chewing process and the mouthfeel was no less than impressive in relation to Example 16 based on non-DC Erythritol. It was also noted that the test panel identified non-DC Xylitol of example 13 and non-DC Maltitol of example 18 as having an impressive watering effect when compared to e.g. the sorbitol-based example.
[0362] Moreover, it was established that the flavor compound, provided an impressive burst, which was perceived very well by the test panel. When pushed to pick a favorite in terms of burst sensation, the test panel pointed at Example 16, the non-DC erythritol example. It is clear that the burst sensation may be obtained through not only the flavor component of the tablet but also clearly through the nature of the non-DC sugar alcohols applied, and in particular the non-DC erythritol. An increased saliva generation also facilitates the user's ability in terms of perceiving the flavor
[0363] As a supplement to the sensory evaluation, the resistance to crunch and friability was measured and indicated in the Examples 13-24, i.e. with reference to a bi-layer tablet with a first layer as indicated in Table 1A and Table 1B and a second layer based primarily on DC xylitol as indicated in Table 2.
[0364] The resistance to crunch is determined according to European Pharmacopoeia 9.1, test method 2.9.8. by using a pharmaceutical resistance to crunch tester model
[0365] Pharma Test type PTB 311.
[0366] Friability is measured according to European Pharmacopoeia 9.1, test method 2.9.7. by using a pharmaceutical friability-tester PTF 10E from Pharma Test.
[0367]
ISX1 refers to the non-DC xylitol example 13,
ISX2 refers to the sorbitol example 14,
ISX3 refers to the non-DC isomalt example 15,
ISX4 refers to the non-DC erythritol example 16,
ISX5 refers to the non-DC mannitol example 17 and
ISX6 refers to the non-DC maltitol example 18.
[0368] The saliva generation as measured with reference to
[0369] The results of the measured saliva generation are illustrated in
[0370] It is noted that the saliva generation from all non-DC sugar alcohols are impressive in the beginning, but it is also noted that saliva generation over time is no less than astonishing in relation to ISX4, i.e. the non-DC erythritol example 16. It is thus noted that the salivation effect is increased a very long time after the major part of non-DC erythritol based tablet has been swallowed or collected during the measurement. It is also observed that the relatively low initial perceived salivation effect of example 14, i.e. the sorbitol-based example is confirming the sensory evaluation as mentioned above.
[0371] It is noted that high salivation and fast release and high sweetness in combination enhances the flavor burst.
Examples 42-43. Preparation of Two-Layer Tablets with an ODT Tablet
[0372]
TABLE-US-00007 TABLE 4 Oral tablet compositions for bi-layered tablets where the layer comprising Pearlitol Flash is an ODT layer. The ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675 g. Amounts are given in wt-% of the respective layer of the tablet. Ex42 Ex43 Raw material (wt %) First layer Non-DC Erythritol 50 50 DC Isomalt — 44.75 Pearlitol Flash** 44.75 — Flavor 2 2 HIS 0.25 0.25 Magnesium 2 2 Stearate Binder HPC 1 1 Raw material (wt % Second layer Pearlitol Flash** — 98.8 DC Xylitol 98.8 — Flavor 1 1 HIS 0.2 0.2 Magnesium 1 1 Stearate Pearlitol Flash** is a trademark of Roquette and is a compound that allies robustness with rapid disintegration and consists of mannitol and starch, specifically developed for disintegrating properties, melting instantaneously in the mouth into a creamy, slightly sweet texture.
TABLE-US-00008 TABLE 4B Oral tablet composition for bi-layered tablets where layer 2 is an ODT layer. The ratio of layer 1 to layer 2 is 75:25. The tablet weight is 1.2 g. Hence the weight of layer 1 is 0.90 g whereas the weight of layer 2 is 0.30 g. Amounts are given in wt-% of the respective layer of the tablet. The ODT layer was seen to disintegrate within 60 seconds. Ex43B Raw material (wt %) First layer Non-DC Erythritol 55 DC Isomalt 34.75 Flavor 4 HIS 0.25 Magnesium Stearate 1 Binder HPC 5 Raw material (wt %) Second layer DC Mannitol 85 Micro Crystalline 5 Cellulose (MCC) Binder CrosPovidone 8 Flavor 1 HIS 1
Examples 44-46 Preparation with Different Levels of Non-DC Sugar Alcohol
[0373]
TABLE-US-00009 TABLE 5 Oral tablet compositions for bi-layered tablets. The ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675 g. Amounts are given in wt-% of the respective layer of the tablet. Ex44 Ex45 Ex46 Rw material (wt %) 1 layer Non-DC Erythritol 5 50 82 DC Isomalt 90.8 43.8 9.8 Flavor 3 3 3 HIS 0.2 0.2 0.2 Binder HPC 1 3 5 Raw material (wt %) Second layer DC Xylitol 91.9 91.9 91.9 DC CaCO3 5 5 5 Flavor 3 3 3 HIS 0.1 0.1 0.1 Resistance to 140 100 55 crunch [N]* Friability 0.70 1.98 5.8 *Method limitation means maximum resistance to crunch which can be measured up to 350N.
Examples 47-50 Preparation with Different Levels of Non-DC Sugar Alcohol
[0374]
TABLE-US-00010 TABLE 6 Oral tablet compositions for bi-layered tablets. The ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675 g. Amounts are given in wt-% of the respective layer of the tablet. Ex47 Ex48 Ex49 Ex50 Rw material (wt %) 1 layer DC Erythritol 0 20 30 50 Non-DC Erythritol 50 30 20 0 DC Isomalt 43.8 43.8 43.8 43.8 Flavor 3 3 3 3 HIS 0.2 0.2 0.2 0.2 Binder HPC 3 3 3 3 Raw material (wt %) Second layer DC Xylitol 91.9 91.9 91.9 91.9 DC CaCO3 5 5 5 5 Flavor 3 3 3 3 HIS 0.1 0.1 0.1 0.1 Resistance to 77 97 109 133 crunch [N]* Friability 2.01 0.73 0.53 0.45 *Method limitation means maximum resistance to crunch which can be measured up to 350N.
Process Flow
[0375] The compositions indicated in the above Tables 4, 4B, 5 and 6 are each processed into two-layer tablets with compositions as outlined in examples 42-50 and 43B.
[0376] For each example 42-50 and 43B, the raw materials are sieved with a 1600-micron sieve and then weighed into the proper amount according to the exampled compositions.
[0377] The weighed amounts are then added to a Turbula mixer in a stainless-steel container and blended at 50 rpm for 5 minutes. If applicable, Magnesium stearate was added after 4 minutes of blending.
[0378] The mixtures are then tableted by means of a Piccola RIVA DC-SC-041-2 or a Fette 3090i.
[0379] The applied molds have circular cross sections with diameters of 16 mm and are hollowed to produce tablets, which are concave and/or curved. Evidently, other mold size and shapes may be applied within the scope of the invention.
[0380] The resulting tablets according to Examples 42-50 and 43B are then obtained by tableting with a suitable pressure force.
[0381] For each tablet of examples 44-50, the second layer is pressed initially at a first relatively low pressure. The blended composition of the so-called first layer is then fed to the mold and a final two-layer tablet is then compressed at higher pressure than the pressure applied on the first layers, thereby producing final two-layer tablets according to Examples 44-50. For examples 42-43 and 43B, the first layer is pressed initially at a first relatively low pressure. The blended composition of the so-called second layer is then fed to the mold and a final two-layer tablet is then compressed at higher pressure than the pressure applied on the first layers, thereby producing final two-layer tablets according to Examples 42-43 and 43B.
[0382] It is noted that the final two-layer tablets of examples 42-43 are 1.5 grams tablets and the ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675 g.
[0383] It is noted that the final two-layer tablets of example 43B are 1.2 grams tablets and the ratio of layer 1 to layer 2 is 75:25. The tablet weight is 1.2 g. Hence the weight of layer 1 is 0.90 g whereas the weight of layer 2 is 0.30 g
[0384] It is noted that the final two-layer tablets of examples 44-50 are 1.5 grams tablets and the ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675 g.
[0385] A specification of relevant compounds applied in the examples explained above are listed below.
HPC: Hydroxy propyl cellulose. Klucel Nutra D from Ashland
Non-DC Xylitol: Xivia C from Dupont
Non-granulated Sorbitol from PharmSorbidex from Cargill
Non-DC Isomalt: Isomalt GS from Beneo Paltinit
Non-DC Mannitol: Pearlitol from Roquette
Non-DC Maltitol: Maltisorb. P200 from Roquette
Non-DC Erythritol: Zerose 16952 from Cargill
DC Erythritol—Zerose 16966 from Cargill
DC Xylitol—Xylitab 200 from Dupont
DC Isomalt—Isomalt DC 101 from Beneo Paltinit
DC Mannitol—Pearlitol SD200 from Roquette
DC Maltitol—Sweetpearl 300 DC from Roquette
DC CaCO3: Scoralite 97 PVP from Scora
Pearlitol Flash is a trademark from Roquette
Micro Crystalline Cellulose (MCC): Avicel PH-105 from FMC
CrosPovidone: Kollidon CL-SF from BASF
Test set-up
[0386] The above two-layer Examples 42-50 and 43B were evaluated with respect to watering effect by a test panel in a time-intensity evaluation set-up. The watering effect is the perceived watering effect by the test panel, i.e. the overall impression of watering effect upon oral administration and commencement of the test.
[0387] The test set-up was composed of 8 test persons in a test panel with 2 repetitions of each variant. Each of the test persons were healthy individuals appointed on an objective basis according to specified requirements. The sensory analysis was performed according to ISO 4121-2003 in testing conditions following ISO 8589. The result is an average of the results of the 8 individuals for 2 repetitions, giving a total of 16 measurements for each variant.
[0388] The 8 test individuals were instructed to swallow saliva before the test was commenced and was not allowed to swallow during testing. The test individuals chewed the samples with a frequency of about 60 chews pr. minute. After 30 seconds, the saliva generated was collected and the weight of the saliva was noted. Before a new test was conducted, the oral cavity was rinsed with water and a time gap of 4 minutes before next test was complied with. Each sample was tested twice by each individual in the test. Hence a total of 16 test results were generated for each sample. Each test individual was allowed to test 6 samples in a test series. At least 30 minutes gap between each test series was complied with.
[0389] The test individuals indicated watering effect intensity on a scale from 0 to 10 where 10 indicates the highest watering effect. The watering effect is measured as a function of time in seconds.
[0390] The ODT layers of Examples 42, 43 and 43B were seen to disintegrate within seconds, such as within 90 seconds and lower.
[0391] Due to the more complex nature of a two-layer tablet two further parameters were evaluated, namely resistance to crunch and friability. The resistance to crunch and friability was measured and indicated in the Examples 44-50.
[0392] The resistance to crunch is determined according to European Pharmacopoeia 9.1, test method 2.9.8. by using a pharmaceutical resistance to crunch tester model Pharma Test type PTB 311.
[0393] Friability is measured according to European Pharmacopoeia 9.1, test method 2.9.7. by using a pharmaceutical friability-tester PTF 10E from Pharma Test.
Watering effect
TABLE-US-00011 TABLE 7 Results of watering effect based on Examples 44-46. The values indicate watering effect intensity on a scale from 0 to 10 where 10 is the highest score on watering effect. The watering effect is measured as a function of time in seconds. Samples were chewed for 30 seconds without swallowing. Watering effect Ex44 Ex45 Ex46 15 s 6.33 7.36 7.66 20 s 7.38 8.37 8.53 25 s 8.36 8.93 9.38
[0394] The results clearly indicate that a high amount of non-DC erythritol (Ex46) is beneficial with respect to watering effect. A low value of non-DC erythritol (Ex44) is less beneficial with respect to watering effect. It is noted that even a slight difference in these values are perceptible. The result also clearly indicates that the watering effect for all samples was higher as a function of time. The value of 9.38 obtained after only 25 seconds for Ex46 was close to the highest perceptible level.
TABLE-US-00012 TABLE 8 Results of watering effect based on Examples 47-50. The values indicate watering effect intensity on a scale from 0 to 10 where 10 is the highest score on watering effect. The watering effect is measured as a function of time in seconds. Samples chewed for 30 seconds without swallowing. Watering effect Ex47 Ex48 Ex49 Ex50 5 s 1.85 1.98 1.95 1.82 10 s 3.67 3.99 3.52 3.43 20 s 6.74 6.16 6.18 5.73 25 s 8.03 7.42 7.61 7.64
[0395] The results indicate that a high amount of non-DC erythritol (Ex47) is beneficial with respect to watering effect. A low value of non-DC erythritol (Ex50) is less beneficial with respect to watering effect, but still acceptable. It is noted that even a slight difference in these values are perceptible. The result also clearly indicates that the watering effect for all samples was higher as a function of time. It was a surprise that the values increased as much as it did with time.
Examples 51-59 Preparation of Powders with Different Particle Size Distribution
[0396]
TABLE-US-00013 TABLE 9 Test comparing different particle size distributions of selected non-DC sugar alcohols. The particles were sieved through a sieve of a mess diameter allowing particles of less than 500 microns to pass and particles of more than 500 microns to be collected. The two fractions were used for further analysis. Raw material powder Ex51 Isomalt non-DC <500 microns Ex52 Isomalt non-DC >500 microns Ex53 Isomalt non-DC Ex54 Xylitol non-DC <500 microns Ex55 Xylitol non-DC >500 microns Ex56 Xylitol non-DC Ex57 Erythritol non-DC <500 microns Ex58 Erythritol non-DC >500 microns Ex59 Erythritol non-DC “non-DC” without particles size indications was the same raw material that was not subject of sieving.
[0397] In this example, powders were tested with respect to total weight of saliva generated upon oral administration.
Non-DC Xylitol: Xivia C from Dupont
Non-DC Isomalt: Isomalt GS from Beneo Paltinit
Non-DC Erythritol: Zerose 16952 from Cargill
[0398] The particles was sieved through a sieve of a mess diameter allowing particles of less than 500 microns to pass and particles of more than 500 microns to be collected. The two fractions were used for further analysis. “non-DC” without particles size indications was the same raw material as indicated above that was not subject of sieving.
Test set-up
[0399] The above powder Examples 51-59 were evaluated with respect to total weight of saliva generated upon oral administration by a test panel.
[0400] The test set-up was composed of 8 test persons with 2 repetitions. The test persons were healthy individuals appointed on an objective basis according to specified requirements. The sensory analysis was performed according to ISO 4121-2003 in testing conditions following ISO 8589.
[0401] The various fractions were tested for total weight of saliva generated according to the following procedure:
[0402] The fractions were tested in a continuous procedure without interruptions in order to obtain reproducible values. A fraction of 1.0 g powder was weighted in a container. In this test, the test individuals were instructed to swallow saliva before the test was commenced and it was not allowed to swallow during the test. The powder was placed in the first 1/3 of the tongue, the head was held forward and it was not allowed to swallow during the test. The test individuals chewed the powder with a frequency of about 60 chews pr. minute. After 60 seconds, the saliva generated was collected and the weight of the saliva was noted. Before a new test was conducted, the oral cavity was rinsed with water and a time gap of 4 minutes before next test was complied with. A series of 2 tests were conducted for the test individual.
TABLE-US-00014 TABLE 10 Results of the total weight of saliva generated based on the preparations in Examples 51-59. Weight of saliva gram Ex51 Ex52 Ex53 Ex54 Ex55 Ex56 Ex57 Ex58 Ex59 Average 3.9 4.0 3.9 4.1 4.5 4.3 4.4 5.1 4.5
[0403] The results can be divided into two major findings:
[0404] Firstly, the results clearly show that non-DC erythritol provided the best result on saliva generation (Ex59), compared to non-DC xylitol (Ex56) and even better than non-DC isomalt (Ex53). It is noted that although non-DC erythritol showed the best result on the total generation of saliva during the test period, both the result of xylitol and isomalt was on a very advantageous level.
[0405] Secondly, the results also very beneficially show that for all three non-DC sugar alcohols, a particle size of more than 500 microns was especially beneficial on saliva generation compared to less than 500 microns. The best results were obtained for non-DC erythritol (Ex58) with a particles size distribution of more than 500 microns, with xylitol of a lower value (Ex55) and isomalt with the lowest (Ex52), but still very advantageous value.
Examples 60-62 Preparation of Powders with Different Sugar Alcohols
[0406]
TABLE-US-00015 TABLE 11 Test comparing selected non-DC sugar alcohols. Raw material powder Ex60 Isomalt non-DC Ex61 Xylitol non-DC Ex62 Erythritol non-DC
[0407] In this example, different sugar alcohols powders were tested with respect to total weight of saliva generated upon oral administration.
Non-DC Xylitol: Xivia C from Dupont
Non-DC Isomalt: Isomalt GS from Beneo Paltinit
Non-DC Erythritol: Zerose 16952 from Cargill
Test set-up
[0408] The above powder Examples 60-62 were evaluated with respect to total weight of saliva generated upon oral administration by a test panel.
[0409] The test set-up was composed of 8 test persons in a test panel with 2 repetitions of each variant. Each of the test persons were healthy individuals appointed on an objective basis according to specified requirements. The sensory analysis was performed according to ISO 4121-2003 in testing conditions following ISO 8589. The result is an average of the results of the 8 individuals for 2 repetitions, giving a total of 164 measurements of each variant.
[0410] The different samples were tested for total weight of saliva generated according to the following procedure:
[0411] A fraction of 1.0 g powder was weighted in a container. In this test, 8 test individual was instructed to swallow saliva before the test was commenced. The powder was placed in the first 1/3 of the tongue, the head was held forward and it was not allowed to swallow during the test. The test individuals chewed the powder with a frequency of about 60 chews pr. minute. After 60 seconds, the saliva generated was collected and the weight of the saliva was noted. Before a new test was conducted, the oral cavity was rinsed with water and a time gap of 4 minutes before next test was complied with. A series of 2 tests were conducted for the test individual. Hence a total of 16 test samples were generated for each raw material powder. Each test individual was allowed to test 6 samples in a test series. At least 30 minutes gap between each test series was required.
TABLE-US-00016 TABLE 12 Results of the total weight of saliva generated based on the preparations in Examples 60-62. Weight of saliva gram Ex60 Ex61 Ex62 Average 4.1 4.2 4.4
[0412] The results clearly show that non-DC erythritol provided the best result (Ex62), compared to non-DC xylitol (Ex61) and even better than non-DC isomalt (Ex60). It is noted that although non-DC erythritol showed the best result on the total generation of saliva during the test period, both the result of xylitol and isomalt was on a very advantageous level.
TABLE-US-00017 TABLE 13 Test comparing different particle size distributions of selected non-DC sugar alcohols. The particles from a commercial grade non-DC sugar alcohol was sieved through a sieve of a mess diameter allowing particles of less than 500 microns to pass and particles of more than 500 microns to be collected. The two fractions were used for further analysis. Raw material powder Ex63 Isomalt non-DC <500 microns Ex64 Isomalt non-DC >500 micron Ex65 Erythritol non-DC <500 microns Ex66 Erythritol non-DC >500 microns
[0413] In this example, powders were tested with respect to total weight of saliva generated upon oral administration by different particle sizes of sugar alcohols.
Non-DC Isomalt: Isomalt GS from Beneo Paltinit
Non-DC Erythritol: Zerose 16952 from Cargill
[0414] The particles was sieved through a sieve of a mess diameter allowing particles of less than 500 microns to pass and particles of more than 500 microns to be collected. The two fractions were used for further analysis. “non-DC” without particles size indications was the same raw material as indicated above that was not subject of sieving.
[0415] Test set-up
[0416] The above powder Examples 63-66 were evaluated with respect to total weight of saliva generated upon oral administration by a test panel.
[0417] The test set-up was composed of 8 test persons in a test panel with 2 repetitions for each variant. Each of the test persons were healthy individuals appointed on an objective basis according to specified requirements. The sensory analysis was performed according to ISO 4121-2003 in testing conditions following ISO 8589. The result is an average of the results of the 8 individuals for 2 repetitions, giving a total of 16 measurements of each variant.
[0418] The different samples were tested for total weight of saliva generated according to the following procedure:
[0419] A fraction of 1.0 g powder was weighted in a container. In this test, 8 test individual was instructed to swallow saliva before the test was commenced. The powder was placed in the first 1/3 of the tongue, the head was held forward and it was not allowed to swallow during the test. The test individuals chewed the powder with a frequency of about 60 chews pr. minute. After 60 seconds, the saliva generated was collected and the weight of the saliva was noted. Before a new test was conducted, the oral cavity was rinsed with water and a time gap of 4 minutes before next test was complied with. A series of 2 tests were conducted for the test individual. Hence a total of 16 test samples were generated for each raw material powder. Each test individual was allowed to test 6 samples in a test series. At least 30 minutes gap between each test series was required.
TABLE-US-00018 TABLE 14 Results of the total weight of saliva generated based on the preparations in Examples 63-66. Weight of saliva gram Ex63 Ex64 Ex65 Ex66 Average 4.0 4.3 4.2 4.6
[0420] The results can be divided into two major findings:
[0421] Firstly, the results very beneficially showed that for the two non-DC sugar alcohols, a particle size of more than 500 microns was especially beneficial compared to less than 500 microns. The best results were obtained for non-DC erythritol (Ex66) with a particles size distribution of more than 500 microns and isomalt with the lowest value (Ex64), but still acceptable value.
[0422] Secondly, the result showed that the generation of saliva was highest for non-DC erythritol compared to non-DC isomalt.
Examples 67-69. Preparation of Two-Layer Tablets with CaCO3
[0423]
TABLE-US-00019 TABLE 15 Oral tablet compositions for bi-layered tablets with different levels of CaCO3. The ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675 g. Amounts are given in wt-% of the respective layer of the tablet. Ex67 Ex68 Ex69 Raw material (wt %) 1 layer Non-DC Erythritol 50 50 50 Sorbitol** 37.4 32.4 27.4 Flavor 2.5 2.5 2.5 HIS 0.1 0.1 0.1 Binder Gum Arabic 5 5 5 DC CaCO3 5 10 15 Raw material (wt %) Second layer DC Xylitol 50 50 50 Sorbitol** 42.9 37.9 32.9 Flavor 2 2 2 HIS 0.1 0.1 0.1 DC CaCO3 5 10 15 Resistance to crunch [N]* 145 115 107 Friability 1.08 1.45 1.87 *Method limitation means maximum resistance to crunch which can be measured up to 350N. **non-granulated sorbitol.
[0424] The compositions indicated in the above Table 15 are each processed into two-layer tablets with compositions as outlined in examples 67-69 and processed according to the process flow of examples 42-50. The compositions of examples 67-69 were further evaluated with respect to watering effect by a test panel in a time-intensity evaluation set-up according to the test set-up of examples 42-50. The compositions are particularly suitable for whitening effects.
Examples 70-72. Preparation of Two-Layer Tablets with Dentifrice
[0425]
TABLE-US-00020 TABLE 16 Oral tablet compositions for bi-layered tablets with dentifrice. The ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675g. Amounts are given in wt-% of the respective layer of the tablet. Raw material Ex70 Ex71 Ex72 (wt %) 1 layer Whitening Cavity Sensitive Non-DC Erythritol 50 50 50 DC Isomalt 20.4 30.9 39.4 Flavor 2.5 2.5 2.5 HIS 0.1 0.1 0.1 Binder Gum Arabic 5 5 0 Binder HPC 0 0 1 Sodium lauryl sulfate 2 1.5 2 DC CaCO3 20 10 5 Raw material (wt %) Second layer Ex70 Ex71 Ex72 DC Xylitol 50 50 50 Sorbitol** 27.9 35.35 28.35 Flavor 2 2 2 HIS 0.1 0.1 0.1 DC CaCO3 10 10 10 Sodium lauryl sulfate 2 1.5 2 Zinc acetate 0 1.0 0 Sodium fluoride 0 0.05 0.05 Sodium bicarbonate 0.5 0 0 Calcium pyrophosphate 7.5 0 0 Potassium Gluconate 0 0 7.5 Resistance to crunch [N]* 145 115 107 Friability 3.08 2.45 1.87 *Method limitation means maximum resistance to crunch which can be measured up to 350N. **non-granulated sorbitol.
[0426] The compositions indicated in the above Table 16 are each processed into two-layer tablets with compositions as outlined in examples 70-72 and processed according to the process flow of examples 42-50. The compositions of examples 70-72 were further evaluated with respect to watering effect by a test panel in a time-intensity evaluation set-up according to the test set-up of examples 42-50. The compositions are particularly suitable for effects associated with dentifrice, such as whitening or sensitive teeth.
Examples 73-75. Preparation of Two-Layer Tablets with Clean Label/Natural Ingredients
[0427]
TABLE-US-00021 TABLE 17 Oral tablet compositions for bi-layered tablets with natural ingredients. The ratio of layer 1 to layer 2 is 55:45. The tablet weight is 1.5 g. Hence the weight of layer 1 is 0.825 g whereas the weight of layer 2 is 0.675 g. Amounts are given in wt-% of the respective layer of the tablet. Ex73 Ex74 Ex75 Raw material (wt %) 1 layer Non-DC Erythritol 50 0 0 DC Erythritol 37.35 0 0 Non-DC Xylitol 0 50 0 DC Xylitol 0 37.35 0 Non-DC Organic cane sugar 0 0 50 DC Organic Tapioca Dextrose 0 0 37.35 Natural Flavors 2.5 2.5 2.5 Stevia Glycosid 0.15 0.15 0.15 Binder acacia gum 5 5 0 DC CaCO3 5 5 5 Raw material (wt %) Second layer DC Erythritol 92.5 0 0 DC Xylitol 0 92.5 0 DC Organic Tapioca Dextrose 0 0 92.5 Natural Flavors 2.5 2.5 2.5 DC CaCO3 5 5 5
[0428] The compositions indicated in the above Table 17 are each processed into two-layer tablets with compositions as outlined in examples 73-75 and processed according to the process flow of examples 42-50. The compositions of examples 73-75 were further evaluated with respect to watering effect by a test panel in a time-intensity evaluation set-up according to the test set-up of examples 42-50. All examples 73-75 were evaluated to have a very beneficial watering effect.